Pharmaceutical company specializing on research, development and commercialization of controlled substances and natural medicines like psychedelics PharmaDrug Inc. (CSE: PHRX) (OTCMKTS: LMLLF) has appointed David Kideckel to the company’s board. David is set to assume his new role with immediate effect.
“We are absolutely thrilled to add the expertise of a member of David’s calibre to our Board of Directors. David’s unique combination of experience in big pharma, biotech and investment banking ideally suits PharmaDrug as it increasingly shifts its focus to a biotech strategy. We look forward to David’s guidance on all matters ranging from scientific to regulatory to capital markets,” said the company’s chairman and CEO, Daniel Cohen.
David Kideckel bears immense experience as he has spent around 20 years in industry and capital markets. More recently he served as the managing director and a senior institutional research analyst at ATB Capital Markets.
David has also served different executive roles at leading biotechnology and pharmaceutical companies including Alexion Pharmaceuticals (acquired by AstraZeneca Plc.), GW Pharmaceuticals (acquired by Jazz Pharmaceuticals) and Johnson & Johnson (JNJ) among others.